Abstract: ［Abstract］Objective The study was aimed to explore the clinical application of iodine oil-docetaxel－suspension in transcatheter arterial chemoembolization （TACE） for primary hepatic carcinoma and find out more effective treatment of TACE to provide a guidance for clinical treatment. Methods 52 patients who were diagnosed with primary hepatic carcinoma during October 2012 to August 2014 were randomly divided into groups A and B， including 32 male and 20 female cases. Group A was given iodine oil-docetaxel-suspension and gemcitabine treatment and group B received iodine oil-epirubicin-suspension and gemcitabine treatment. A comparison was conducted in the curative effect， liver function， quality of life， KPS score， AFP changes， the cumulative survival and other changes of patients between the two groups. Results There were no significant differences in gender， age， HBsAg （+）and the Child-Pugh score of 52 cases（P > 0.05）. The disease control rate in groups A and B was 21.8% （7 cases）and 20% （4 cases）， and there was no significant difference between the two groups（P > 0.05）. The tumor response rate in groups A and B was 84.3% （27 cases） and 80% （16 cases）， with no significant difference（P > 0.05）. There were no significant differences in PR，SD and PD between the two groups （P > 0.05）. Postoperative serum AFP of patients in the two groups was significantly decreased compared with preoperative （P < 0.05）. The mean survival time and median survival period of group A were 14.4 and 13.7 months， while those of group B were 12.1 and 9.7 months，respectively. There were no significant differences in 6 and 24 months survival rates between the two groups（P > 0.05）， but there were significant differences in 12 and 18 months（P < 0.05）. Compared with group B，liver function was improved in group A after TACE， with a significant difference（P < 0.05）. In the quality of life， KPS scores of two groups increased gradually within 3 months after TACE，but reduced after 3 months. The KPS scores of group A were higher than those of group B on 1， 6 and 12 months after TACE（P < 0.05）. Conclusion　The interventional therapy of two groups are both effective in treating primary hepatic carcinoma. But iodine oil-docetaxel-suspension TACE for primary hepatic carcinoma has advantages in improving the quality of life， prolonging the survival time，reducing the damage of liver function，and inhibiting tumor cell growth，whicht is worthy of clinical promotion.